Key facts
- Reccan’s last known valuation is $17.6M (Mar 2022).
- It has raised $4.6M; the latest was Grant ($1.0M) in May 2025.
- Notable investors include Nordic Mentor Network For Entrepreneurship, Cardeon (Private Equity), Christer Fåhraeus, Fårö Capital, Horizon Europe — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Reccan
- ·The full record, as it builds
Funding rounds
No funding rounds for Reccan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reccan
Developer of diagnostic tools designed to improve the detection and management of pancreatic cancer. The company applies translational research methodologies grounded in clinical data and national registries to develop and validate novel biomarkers, enabling oncology researchers and healthcare providers to access advanced diagnostic capabilities for early-stage tumor identification, improved clinical outcomes, and biomarker-driven decision-making in pancreatic cancer treatment.
- Sector
- Healthcare
- HQ
- Lund, Sweden
- Founded
- 2014
- Employees
- 2
- Website
- reccandiagnostics.com/
- Ownership
- Privately Held (backing)
Reccan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reccan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reccan in its N-PORT filings yet. We sweep new filings monthly.